Oppenheimer downgraded 89bio (ETNB) to Perform from Outperform and removed the firm’s prior $30 price target on shares after competitor Akero Therapeutics (AKRO) announced data from its own phase IIb SYMMETRY study of efruxifermin in patients with F4 nonalcoholic steatohepatitis, or NASH. Akero’s study missed the primary endpoint of greater than or equal to 1-stage fibrosis improvement by week-36 and the firm has “reduced confidence” for the FGF21 approach to address F4 NASH patients, the analyst tells investors. The firm also has “increased optimism” for Madrigal Pharmaceuticals’ (MDGL) resmetirom to capture the F2-3 NASH market, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ETNB:
- 89bio price target lowered to $27 from $34 at RBC Capital
- 89bio down 27% after Akero reports NASH trial data
- 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cantor Fitzgerald biotech analysts to hold an analyst/industry conference call
- 3 Best Stocks to Buy Now, 9/22/2023, According to Top Analysts